Unknown

Dataset Information

0

Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy.


ABSTRACT: High systemic doses of adeno-associated viruses (AAVs) have been associated with immune-related serious adverse events (SAEs). Although AAV was well tolerated in preclinical models, SAEs were observed in clinical trials, indicating the need for improved preclinical models to understand AAV-induced immune responses. Here, we show that mice dual-dosed with AAV9 at 4-week intervals better recapitulate aspects of human immunity to AAV. In the model, anti-AAV9 immunoglobulin G (IgGs) increased in a linear fashion between the first and second AAV administrations. Complement activation was only observed in the presence of high levels of both AAV and anti-AAV IgG. Myeloid-derived pro-inflammatory cytokines were significantly induced in the same pattern as complement activation, suggesting that myeloid cell activation to AAV may rely on the presence of both AAV and anti-AAV IgG complexes. Single-cell RNA sequencing of peripheral blood mononuclear cells confirmed that activated monocytes were a primary source of pro-inflammatory cytokines and chemokines, which were significantly increased after a second AAV9 exposure. The same activated monocyte clusters expressed both Fcγ and complement receptors, suggesting that anti-AAV-mediated activation of myeloid cells through Fcγ receptors and/or complement receptors is one mechanism by which anti-AAV antigen complexes may prime antigen-presenting cells and amplify downstream immunity.

SUBMITTER: Emami MR 

PROVIDER: S-EPMC10512012 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy.

Emami Michael R MR   Espinoza Alejandro A   Young Courtney S CS   Ma Feiyang F   Farahat Philip K PK   Felgner Philip L PL   Chamberlain Jeffrey S JS   Xu Xiangmin X   Pyle April D AD   Pellegrini Matteo M   Villalta S Armando SA   Spencer Melissa J MJ  

Molecular therapy. Methods & clinical development 20230612


High systemic doses of adeno-associated viruses (AAVs) have been associated with immune-related serious adverse events (SAEs). Although AAV was well tolerated in preclinical models, SAEs were observed in clinical trials, indicating the need for improved preclinical models to understand AAV-induced immune responses. Here, we show that mice dual-dosed with AAV9 at 4-week intervals better recapitulate aspects of human immunity to AAV. In the model, anti-AAV9 immunoglobulin G (IgGs) increased in a l  ...[more]

Similar Datasets

| S-EPMC6171037 | biostudies-literature
| S-EPMC8797140 | biostudies-literature
| S-EPMC6455975 | biostudies-literature
| S-EPMC8533196 | biostudies-literature
| S-EPMC11319415 | biostudies-literature
| S-EPMC10557455 | biostudies-literature
| S-EPMC11750718 | biostudies-literature
| S-EPMC10380683 | biostudies-literature
| S-EPMC9678653 | biostudies-literature
| S-EPMC3277234 | biostudies-literature